( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 1 (AECOPD ( (AECOPD (chronicobstructivepulmonarydisease,copd, 7 20245,40 8.2% /, 2020 5, 3 0.5~3.5, (AECOPD,,2006 AECOPD 4.3%, 9545,AECOPD 11598 AECOPD,AECOPD 1.AECOPD :AECOPD,, 2.AECOPD : AECOPD -, AECOPD, AECOPD, AECOPD, 1/3 AECOPD 3.AECOPD :AECOPD, 4.AECOPD :AECOPD β 2, (FEV 1 (PaO 2, AECOPD 5.AECOPD :AECOPD, :1 ;2 ;3 ;4 ; 5-4 AECOPD,78% AECOPD, AECOPD,, 1.AECOPD : AECOPD, 50% AECOPD, 64% AECOPD, AECOPD AECOPD AECOPD, :,Email:caibq2009@hotmail.com,Email:bai.chunxue@zs-hospital.sh.cn
2 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1,AECOPD AECOPD,,, AECOPD, 25% AECOPD,, 2.AECOPD :40%~60% AECOPD,, 25%, 50% 8 α,,, AECOPD AECOPD, ( Anthonisen Ⅰ,,,CD8 + AECOPD,, 50%, AECOPD, 3.AECOPD :,, 10μm (PM 10 AECOPD, AECOPD, AECOPD 1. :AECOPD, (, ( X 2. :,AECOPD ( AECOPD 3. :10%~30% AECOPD, :,, AECOPD 4.AECOPD :AECOPD, AECOPD ( 1,,,,, AECOPD,,, AECOPD,
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 3 1 AECOPD : FEV1 (, AECOPD,,2004 (ATS/ (ERS, AECOPD :Ⅰ, ;Ⅱ, ;Ⅲ, ICU ( 5. :(1 : ( (2X :, X X AECOPD, (3 :,,PaO 2<60 mm Hg ( PaCO 2>50 mm Hg, PaO 2< 50mm Hg,PaCO 2>70mm Hg,pH<7.30,, ICU (4 :FEV 1<1L,, (5 : (6 : AECOPD, ( (, (7 :,, GOLD Ⅲ GOLD Ⅳ,,, AECOPD AECOPD, ( (,, 4,FEV 1 30%, (, AECOPD, AECOPD (,, ICU AECOPD, 1. :(1, ;(2 ;(3 ( ;(4 ( ;(5 ;(6 ;(7 ;(8 2. ICU :(1 ;(2 ( ;(3 (NIV, (PaO 2<40mm Hg ( (ph<7.25;(4 ;(5,
4 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 3.AECOPD :(1Ⅰ : ( 2;(2Ⅱ : ( 3;(3Ⅲ : ICU ( ( 4 2, AECOPD β 2- (, 30~40mg,,10~14d;, 3 - ( - β- -, : ( AECOPD 4 ICU AEOCPD β 2-,, 30~40mg/d,10~14d,,10~14d ( /, ( (, β-, : ( ( AECOPD AECOPD (PaO 2>60mm Hg SaO 2>90%, CO 2 Venturi, Venturi 30min, CO 2 (
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 5 ( β 2- β 2- AECOPD, AECOPD /, 1. :AECOPD β 2- AECOPD β 2-, β 2- AECOPD, ( β 2-,,, ;,,, 2~4 :(1 (SalbutamolSulfateSolutionforInhalation:5mg/ml, 4 0.5~1.0ml(2.5~5.0mg, 2.0~2.5ml (2 (Ipratropium BromideSolutionforInhalation:, 6~8L/min, 500μg/2ml (3 :2.5ml 0.5 mg 3.0mg( 2.5 mg ( 12 3~4, 2.5ml 2. ( :, AECOPD β 2-, β 2-12~24h,,,,,, 24h, ;, 5~12μg/ml,, ( 5μg/ml β 2-,, ( AECOPD,, (FEV 1,,, 30~40mg/d, 10~14d, (Budesonide SuspensionforInhalation 1~2mg/, 2, 2~4ml : AECOPD, AECOPD 8mg 40mg ( 1. :AECOPD, AECOPD
6 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 AECOPD :1 AECOPD, :, ;2 ;3, AECOPD 2. : (, (, AECOPD, ( 3. : (,, 5~10d, 4. :AECOPD 2 A : ;B, :1 ;2 (>4 / ( 3 ;3 (FEV 1<30%;4 ( 2 >10mg/d, /,,, 750mg/24h 500mg, 2 ( :2011, β 3d, ( 5. :,, ;, AECOPD,, 10%~20% AECOPD :1, ( ;2 ;3 ;4, :1 ;2 ;3,, ( 1. AECOPD:, RNA, (,Zanamivir,, 2. AECOPD :2011 ( : AECOPD ( 2
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 7 d ( AECOPD,, (Doxapram ( ;, ;, ( ; ( ( AECOPD :(1, PaO 2, SaO 2>90%, ;(2, PaCO 2 ;(3,, ; (4 ;(5 : AECOPD, ( (NIV AECOPD,NIV 5 AECOPD, ph, PaCO 2,, 5 AECOPD NIV NIV : 1 [ ph 7.35 ( PaCO2>45mm Hg],,, NIV (, 1. :, NIV,, 2. : NIV : (CPAP / (PCV/VCV (PAV + (PSV+PEEP,, : (EPAP 2~4cm H 2O,, ; (IPAP 4~8cm H 2O,, 3.NIV AECOPD : 6
8 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 6 NIV AECOPD SpO2 ph PaCO2 PaO2,,, ( ( AECOPD, NIV, NIV NIV,, AECOPD 7 7 AECOPD NIV NIV ( NIV, <50 /min,,, NIV 1. : (SIMV PSV,, PAV SIMV+PSV PSV, PSV,,,, SIMV, PAV, ( 8 8 AECOPD (A/C; (SIMV; (PSV, (VT:7~9ml/kg, (RR:10~15 /min, (I E:1 2/1 3, >60L/min (FiO2 SaO2>90% PEEPe, (Pplat<30cm H2O, 2. : (dynamicpulmonaryhyperinflation,dph (PEEPi AECOPD,, (PEEPe,, (1 : 7~9ml/kg, 30cm H 2O ( 35~40cm H 2O, DPH ;, PaCO 2, PaCO 2 (2 :, DPH, 10~15 /min (3 : (>60L/min,
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 9 (100L/min, - 1 2 1 3,, AECOPD,, AECOPD, PaCO 2 (4PEEPe: PEEPe AECOPD,,, PEEPe PEEPi 80%, DPH PEEPi, 4~6cm H 2O PEEPe (5 (FiO 2 :AECOPD, ( 3. AECOPD :, /, :PEEPi (Ppeak (Pplat (VT (Flow AECOPD, :1PEEPi;2 Cst= /( - PEEP;3 R=( - / AECOPD :(1 : (<35~40cm H 2O (<30cm H 2O, AECOPD, ( DPH,, DPH (2 PEEPi:PEEPi PEEPi :1 ;2 ( ;3 ;4 PEEPi, (3 :,,, (4 : CO 2, ph PaCO 2, PaCO 2 AECOPD, AECOPD, AECOPD,,, 40%,,pH> 7.35,PaCO 2<50mm Hg,, AECOPD, ( AECOPD,,,,, AECOPD,, 1. :,,,,,, 2. :AECOPD,, :1 ;2, ;3 ;4 AECOPD AECOPD,
10 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1,,,, K, 1/2~1/3,,0.25 mg/d, 0.125mg/d, 3. :AECOPD,,,,,AECOPD,,,,, 0.2~ 0.4mg, 5mg, 40~80mg,3 /d, 50~100mg, 15min 1,, β-, β 1-, (metoprolol (bisoprolol (, AECOPD,,AECOPD,AECOPD 24.7%, 30% AECOPD,, AECOPD, AECOPD 1.AECOPD :1, ;2AECOPD ;3AECOPD,,, AECOPD,, AECOPD ( PaO 2 60mm Hg 2.AECOPD :1 CT ;2 D-, D- ;3 - AECOPD ;4,, 3.AECOPD : AECOPD,, 4.AECOPD : ( 18 ( 19 1. :1, β 2- (, ;2 β 2-4 1 ;3, ;4, ;5 12~24h;6 12~24h;7 ( ;8 ( ;9 AECOPD,, 4~8, 2. : 6, ; (FEV 1 ;
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 11 (, (mmrc (CAT,,,,, 3 ( 3.AECOPD :AECOPD, -4, AECOPD /, AECOPD N-,, N- AECOPD, 3 ( 9, AECOPD, AECOPD 9 AECOPD (fluticasone (budesonide (indacaterol (salmeterol (fomoterol (tiotropium -4 (roflumilast (theophyline (carbocistenine N-, AECOPD, 2011 GOLD : AECOPD 1,, (AECOPD ( ( ( ( ( ( ( ( ( ( (
12 ( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 ( ( ( ( ( ( : [1] GOLDExecutiveCommitee.Globalstrategyforthediagnosis,management,andpreventionofchronicobstructivepulmonarydisease (Revised2011.www.goldcopd.com [2] ZhongN,WangC,Yao W,etal.PrevalenceofchronicobstructivepulmonarydiseaseinChina:alarge,population-basedsurvey.AmJ RespirCritCareMed,2007,176 :753-760. [3] PereraPN,ArmstrongEP,SherrilDL,etal.AcuteexacerbationsofCOPDintheUnitedStates:inpatientburdenandpredictorsof costsandmortality.copd,2012,9:131-141. [4] ChenYH,Yao WZ,CaiBQ,etal.Economicanalysisinadmitedpatientswithacuteexacerbationofchronicobstructivepulmonary disease.chin MedJ(Engl,2008,121:587-591. [5],. (2011.,2012,11:1-12. [6] CeliBR,MacNee W,ATS/ERSTaskForce.StandardsforthediagnosisandtreatmentofpatientswithCOPD:asummaryoftheATS/ ERSpositionpaper.EurRespirJ,2004,23:932-946. [7] KoutsokeraA,StolzD,LoukidesS,etal.SystemicbiomarkersinexacerbationsofCOPD:theevolvingclinicalchalenge.Chest,2012, 141:396-405. [8] BertoletiL,QuenetS,MismetiP,etal.ClinicalpresentationandoutcomeofvenousthromboembolisminCOPD.EurRespirJ,2012,39: 862-868. [9] Woodhead M,BlasiF,EwigS,etal.Guidelinesforthemanagementofadultlowerrespiratorytractinfections--summary.Clin Microbiol Infect,2011,17(Suppl6:1-24. [10].,2006,3:28-31. [11].,2012,11:105-110. [12]. (2007.,2007,19:513-518. [13],,.,2004,3:126-128. [14] BritishThoracicSocietyStandardsofCareCommitee.Non-invasiveventilationinacuterespiratoryfailure.Thorax,2002,57:192-211. [15] WiseAL.Chronicobstructivelungdisease:ClinicalCourseand Management.In:FishmanAPeds:Fishman spulmonarydiseasesand Disorders.4ed,New York:McGraw-Hil,2008,729-746. [16] RizkalahJ,ManSF,SinDD.PrevalenceofpulmonaryembolisminacuteexacerbationsofCOPD:asystematicreviewandmetaanalysis. Chest,2009,135:786-793. [17] AlbertP,CalverleyPM.Drugs(includingoxygeninsevereCOPD.EurRespirJ,2008,31:1114-1124. [18]. (.,2001,24:259-264. [19].,2010,49:74-81. [20],,.,2008,36:26-28. [21],.,2012,33:1310-1312. [22],,.,2000,23: 212-216. [23].,2009,32:86-98.
( 2013 2 7 1 ChinJAsthma(ElectronicEdition,February2013,Vol.7,No.1 13 [24] MackayAJ,HurstJR.COPDexacerbations:causes,prevention,andtreatment.MedClinNorthAm,2012,96 :789-809. [25] BanA,IsmailA,HarunR,etal.ImpactofclinicalpathwayonclinicaloutcomesinthemanagementofCOPDexacerbation.BMCPulm Med,2012,12:27. [26] BruloteCA,LangES.Acuteexacerbationsofchronicobstructivepulmonarydiseaseintheemergencydepartment.Emerg MedClin NorthAm,2012,30 :223-247. [27]. (2011.,2012,35:249-256. [28] LlorC,MoragasA,HernándezS,etal.Eficacyofantibiotictherapyforacuteexacerbationsofmildtomoderatechronicobstructive pulmonarydisease.amjrespircritcaremed,2012,186 :716-723. [29],,. 2011 (.,2012,32:1201-1206. [30] Han MK,MartinezFJ.Pharmacotherapeuticapproachestopreventingacuteexacerbationsofchronicobstructivepulmonarydisease.Proc Am ThoracSoc,2011,8 :356-362. [31] ZhengJP,KangJ,HuangSG,etal.Efectofcarbocisteineonacuteexacerbationofchronicobstructivepulmonarydisease (PEACE Study:arandomisedplacebo-controledstudy.Lancet,2008,371:2013-2018. ( :2012-11-18 (AECOPD. (AECOPD ( [J/CD]. :,2013,7(1:1-13.